Stuart Therapeutics is testing the first collagen mimetic peptide for dry eye disease – a novel mechanism that produced Week 1 staining gains vs. vehicle greater than any reported result for an approved therapy in their recent Phase 3.
A single CAR-T dose still takes up to 33 days to manufacture, at $170,000–$220,000 per batch.
Co-founder and CEO Sophie James on modified monosaccharides, intracellular glycan processing, and a rare-disease-first route into fibrosis, oncology, and Alzheimer's.
Stuart Curbishley on how adthera bio is tackling the biggest bottleneck in cell and gene therapy: getting therapies manufactured at scale.
Venture investment in cell and gene therapy has crashed by nearly $8 billion since 2021's peak, putting the field's translation to patients at risk.
With over 2,000 cell and gene therapies in clinical trials globally, the industry’s reliance on manual, labour-intensive manufacturing is an existential bottleneck.
With zero FDA-approved personalised iPSC therapies on the market, the vast majority of patients who could benefit from regenerative treatments still can’t access them.
New options emerged in PBC-associated itch, plaque psoriasis, neurologic Hunter syndrome, and platinum-resistant ovarian cancer.
The first gene therapy for severe LAD-I achieves 100% HSCT-free survival with sustained CD18 expression through 42 months in paediatric patients lacking a matched donor
The biotech industry destroys billions in shareholder value every year - failed trials, depleted cash, and abandoned pipelines leaving investors with nothing.
90% of oncology drugs fail in clinical trials - costing billions and, more importantly, delaying life-saving treatments for patients who need them now.
Will large pharma's AI adoption and deployment to drug development redefine biotech's role and business model?
38 trillion bacteria live in your gut — yet most microbiome tests can only identify them at the genus level, missing the strains that actually matter.
Hundreds of thousands of spine fusions are performed each year, but implant choice is still often limited to standard sizes.
Personalis is betting that detecting relapse at the molecular level, before it becomes radiographically obvious, can change how cancer is monitored and managed.
